Patents by Inventor Stephen Moss

Stephen Moss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10556007
    Abstract: The invention provides an antibody or fragment thereof that specifically binds to human Lrg1.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: February 11, 2020
    Assignee: UCL Business LTD
    Inventors: Vineeta Tripathi, Rose Sheridan, John Greenwood, Stephen Moss
  • Publication number: 20190309009
    Abstract: This disclosure relates to uridine di phosphate (UDP) derivatives, compositions comprising therapeutically effective amounts of those UDP derivatives and methods of using those derivatives or compositions in treating disorders that are responsive to ligands, such as agonists, of P2Y6 receptor, e.g., neuronal disorders, including neurodegenerative disorders (e.g., Alzheimer's disease) and traumatic CNS injury, as well as pain.
    Type: Application
    Filed: December 3, 2018
    Publication date: October 10, 2019
    Inventors: Philip G. Haydon, Jinbo Lee, Jinghui Dong, Stephen Moss, Raquel Revilla-Sanchez
  • Publication number: 20190233970
    Abstract: A process, for example a continuous process, for making an article of manufacture containing a fibrous structure and more particularly a process for making an article of manufacture containing a fibrous structure, such as a soluble fibrous structure, containing soluble filaments is provided.
    Type: Application
    Filed: January 17, 2019
    Publication date: August 1, 2019
    Inventors: Anthony Edward Reed, Michael Sean Pratt, Paul R. Mort, III, Stephen Robert Glassmeyer, Dinah Achole Nyangiro, Mark William Hamersky, Richard Allen Diemar, Jeffrey Moss Vaughn, Gavin John Broad, Gregory Charles Gordon, Frank William Denome, Mark Robert Sivik, Andreas Josef Dreher
  • Publication number: 20190233974
    Abstract: A process, for example a continuous process, for making an article of manufacture containing a fibrous structure, for example a composite structure, and more particularly to a process for making an article of manufacture containing a fibrous structure, such as a soluble fibrous structure, containing soluble filaments is provided.
    Type: Application
    Filed: January 17, 2019
    Publication date: August 1, 2019
    Inventors: Anthony Edward Reed, Michael Sean Pratt, Paul R. Mort, III, Stephen Robert Glassmeyer, Dinah Achola Nyangiro, Mark William Hamersky, Richard Allen Diemar, Jeffrey Moss Vaughn, Gavin John Broad, Gregory Charles Gordon, Frank William Denome, Mark Robert Sivik, Andreas Josef Dreher
  • Patent number: 9949910
    Abstract: A method of improving the rinsability of a cleansing composition comprising an isethionate ester surfactant of formula R6COOCH2CH2SO3?M+ the method comprising incorporating into the composition one or more compounds of formula (I) wherein R1 and R6 each independently represents a C4-36 substituted or unsubstituted hydrocarbyl group; each of R2, R3, R4 and R5 independently represents a hydrogen atom or a C1-4 alkyl group and wherein at least one of R2, R3, R4 and R5 is not hydrogen and M+ represents a cation.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: April 24, 2018
    Assignee: INNOSPEC LIMITED
    Inventors: John Nucci, Stephen Moss O'Connor
  • Publication number: 20180028609
    Abstract: The invention provides an antibody or fragment thereof that specifically binds to human Lrg1.
    Type: Application
    Filed: February 22, 2016
    Publication date: February 1, 2018
    Applicant: UCL Business PLC
    Inventors: Vineeta TRIPATHI, Rose SHERIDAN, John GREENWOOD, Stephen MOSS
  • Patent number: 9708397
    Abstract: This invention relates to the field of molecular physiology. Specifically, this invention relates to the treatment of vasculoproliferative conditions, especially those of the eye and in the treatment of tumours that exhibit vascular proliferation. Levels of leucine-rich alpha-2-glycoprotein (Lrg1) have been demonstrated to be increased in patients suffering from such conditions and animal models of such conditions. Antagonists of Lrg1 can be used to treat vasculoproliferative conditions.
    Type: Grant
    Filed: June 23, 2014
    Date of Patent: July 18, 2017
    Inventors: John Greenwood, Stephen Moss, Xiaomeng Wang
  • Patent number: 9599657
    Abstract: Approaches for performing in line wafer testing are provided. An approach includes a method that includes generating a radio frequency (RF) test signal, and applying the RF test signal to a device under test (DUT) in a wafer using a buckling beam probe set with a predefined pitch. The method also includes detecting an output RF signal from the DUT in response to the applying the RF test signal to the DUT, and sensing at least one frequency component of the detected output RF signal.
    Type: Grant
    Filed: January 3, 2013
    Date of Patent: March 21, 2017
    Assignee: GLOBALFOUNDRIES INC.
    Inventors: Hanyi Ding, John Ferrario, Barton E. Green, Stephen Moss, Mustapha Slamani
  • Patent number: 9593298
    Abstract: A method of preparing a component of a personal care bar, the method comprising: (a) providing a composition comprising an isethionate surfactant at a temperature of at least 20° C.; (b) combining the composition comprising the isethionate surfactant with a synthetic 5 wax and optional further components at a temperature of at least 120° C.; and (c) cooling the mixture obtained in step (b).
    Type: Grant
    Filed: June 14, 2012
    Date of Patent: March 14, 2017
    Assignee: Innospec Limited
    Inventors: Phillip Loraine Cotrell, Philip Arie Matena, Stephen Moss O'Connor
  • Patent number: 9545392
    Abstract: A pharmaceutical composition is provided comprising a vitamin E derivative, an anionic phopholipid-binding protein, an anionic phospholipid and a sterol. Also provided is a method for preparing a composition for delivering a cargo to a subject comprising a) forming liposomes from a vitamin E derivative, an anionic phospholipid-binding protein such as annexin, an anionic phospholipid such as phosphatidylserine and a sterol; and b) encapsulating the cargo in the liposomal composition.
    Type: Grant
    Filed: March 29, 2010
    Date of Patent: January 17, 2017
    Assignee: UCL BUSINESS PLC
    Inventors: Francesca Cordeiro, Stephen Moss, Katy Coxon, James Duggan
  • Patent number: 9539203
    Abstract: The invention relates to a carrier for delivering agents to the posterior region of the eye, the carrier comprising a Vitamin E derivative, especially tocopherol. The carrier may also comprise a cell death marker, such as an annexin.
    Type: Grant
    Filed: December 19, 2008
    Date of Patent: January 10, 2017
    Assignee: UCL BUSINESS PLC
    Inventors: Francesca Cordeiro, Stephen Moss
  • Publication number: 20160318968
    Abstract: This disclosure relates to uridine di phosphate (UDP) derivatives, compositions comprising therapeutically effective amounts of those UDP derivatives and methods of using those derivatives or compositions in treating disorders that are responsive to ligands, such as agonists, of P2Y6 receptor, e.g., neuronal disorders, including neurodegenerative disorders (e.g., Alzheimer's disease) and traumatic CNS injury, as well as pain.
    Type: Application
    Filed: January 4, 2016
    Publication date: November 3, 2016
    Inventors: Philip G. Haydon, Jinbo Lee, Jinghui Dong, Stephen Moss, Raquel Revilla-Sanchez
  • Patent number: 9227993
    Abstract: This disclosure relates to uridine diphosphate (UDP) derivatives, compositions comprising therapeutically effective amounts of those UDP derivatives and methods of using those derivatives or compositions in treating disorders that are responsive to ligands, such as agonists, of P2Y6 receptor, e.g., neuronal disorders, including neurodegenerative disorders (e.g., Alzheimer's disease) and traumatic CNS injury, as well as pain.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: January 5, 2016
    Assignee: TUFTS UNIVERSITY
    Inventors: Philip G. Haydon, Jinbo Lee, Jinghui Dong, Stephen Moss, Raquel Revilla-Sanchez
  • Publication number: 20150132226
    Abstract: This invention relates to the field of molecular physiology. Specifically, this invention relates to the prevention and/or treatment of cancer. Leucine-rich alpha-2-glycoprotein (Lrg1) has been demonstrated to be expressed in a range of cancer cells. Antagonists of Lrg1 can be used to prevent and/or treat cancer by an effect on neoplastic cells.
    Type: Application
    Filed: March 8, 2013
    Publication date: May 14, 2015
    Inventors: John Greenwood, Stephen Moss, Xiaomeng Wang
  • Patent number: 9014457
    Abstract: The invention relates to methods of diagnosis, particularly methods of staging and diagnosing neurodegenerative diseases using images of cell death in the eye.
    Type: Grant
    Filed: November 5, 2010
    Date of Patent: April 21, 2015
    Assignee: UCL Business PLC
    Inventors: Stephen Moss, Maria Francesca Cordeiro, Steven Dakin
  • Publication number: 20150045319
    Abstract: This disclosure relates to uridine diphosphate (UDP) derivatives, compositions comprising therapeutically effective amounts of those UDP derivatives and methods of using those derivatives or compositions in treating disorders that are responsive to ligands, such as agonists, of P2Y6 receptor, e.g., neuronal disorders, including neurodegenerative disorders (e.g., Alzheimer's disease) and traumatic CNS injury, as well as pain.
    Type: Application
    Filed: July 3, 2014
    Publication date: February 12, 2015
    Inventors: Philip G. Haydon, Jinbo Lee, Jinghui Dong, Stephen Moss, Raquel Revilla-Sanchez
  • Publication number: 20140377277
    Abstract: This invention relates to the field of molecular physiology. Specifically, this invention relates to the treatment of vasculoproliferative conditions, especially those of the eye and in the treatment of tumours that exhibit vascular proliferation. Levels of leucine-rich alpha-2-glycoprotein (Lrg1) have been demonstrated to be increased in patients suffering from such conditions and animal models of such conditions. Antagonists of Lrg1 can be used to treat vasculoproliferative conditions.
    Type: Application
    Filed: June 23, 2014
    Publication date: December 25, 2014
    Inventors: John GREENWOOD, Stephen MOSS, Xiaomeng WANG
  • Publication number: 20140342974
    Abstract: A method of improving the rinsability of a cleansing composition comprising an isethionate ester surfactant of formula R6COOCH2CH2SO3?M+ the method comprising incorporating into the composition one or more compounds of formula (I) wherein R1 and R6 each independently represents a C4-36 substituted or unsubstituted hydrocarbyl group; each of R2, R3, R4 and R5 independently represents a hydrogen atom or a C1-4 alkyl group and wherein at least one of R2, R3, R4 and R5 is not hydrogen and M+ represents a cation.
    Type: Application
    Filed: December 20, 2012
    Publication date: November 20, 2014
    Inventors: John Nucci, Stephen Moss O'Connor
  • Patent number: 8790647
    Abstract: This invention relates to the field of molecular physiology. Specifically, this invention relates to treatment of vasculoproliferative conditions, especially those of the eye and in the treatment of tumours that exhibit vascular proliferation. Levels of leucine-rich alpha-2-glycoprotein (Lrg1) have been demonstrated to be increased in patients suffering from such conditions and animal models of such conditions. Antagonists of Lrg1 can be used to treat vasculoproliferative conditions.
    Type: Grant
    Filed: September 6, 2010
    Date of Patent: July 29, 2014
    Assignee: UCL Business PLC
    Inventors: John Greenwood, Stephen Moss, Xiaomeng Wang
  • Patent number: 8771645
    Abstract: The invention relates to the use of a cell death marker labelled with a wavelength-optimised label for identifying cell death in the eye. Suitable cell death markers are the Annexins and fragments and derivatives thereof. The invention also relates to a pharmaceutical composition comprising a cell death marker labelled with a wavelength-optimised label and a method for monitoring cell death in the eye using a cell death marker labelled with a wavelength-optimised label.
    Type: Grant
    Filed: December 15, 2008
    Date of Patent: July 8, 2014
    Assignee: UCL Business PLLC
    Inventors: Francesca Cordeiro, Stephen Moss, Frederick Fitzke